EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission

Krishna K Paul, Christian G Frey, Stanley Troung, Laura Vita Q Paglicawan, Kathryn A Cunningham, T Preston Hill, Lauren G Bothwell, Georgiy Golovko, Yeoshina Pillay, Dietrich Jehle

Western Journal of Emergency Medicine · 2024

DOI: 10.5811/westjem.18569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Western Journal of Emergency Medicine, 2024. Verfasst von Krishna K Paul und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Buprenorphine, Naloxone Drug Combination, Narcotic Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

As fentanyl has become more readily available, opioid-related morbidity and mortality in the United States has increased dramatically. Preliminary studies suggest that high-affinity, partial mu-opioid receptor agonists such as the combination product buprenorphine-naloxone may reduce mortality from overdose and promote remission. With the escalating prevalence of opioid use disorder (OUD), it is essential to evaluate the effectiveness of opioid agonists like buprenorphine-naloxone. This study examines mortality and remission rates for OUD patients prescribed buprenorphine-naloxone to determine the efficacy of this treatment toward these outcomes.

Methods

We carried out a retrospective analysis using the US Collaborative Network database in TriNetX, examining de-identified medical records from nearly 92 million patients across 56 healthcare organizations. The study spanned the years from January 1, 2017–May 13, 2022. Cohort 1 included OUD patients who began buprenorphine-naloxone treatment within one-year post-diagnosis, while Cohort 2, the control group, consisted of OUD patients who were not administered buprenorphine. The study measured mortality and remission rates within a year of the index event, incorporating propensity score matching for age, gender, and race/ethnicity.

Results

Prior to propensity matching, we identified a total of 221,967 patients with OUD. Following exclusions, 61,656 patients treated with buprenorphine-naloxone showed 34% fewer deaths within one year of diagnosis compared to 159,061 patients who did not receive buprenorphine (2.6% vs 4.0%; relative risk [RR] 0.661; 95% confidence interval [CI] 0.627–0.698; P < 0.001). The remission rate was approximately 1.9 times higher in the buprenorphine-naloxone group compared to the control group (18.8% vs 10.1%; RR 1.862; 95% CI 1.812–1.914; P < 0.001). After propensity matching, the effect on mortality decreased but remained statistically significant (2.6% vs 3.0%; RR 0.868; 95% CI 0.813–0.927; P < 0.001) and the remission rate remained consistent (18.8% vs 10.4%; RR 1.812; 95% CI 1.750–1.876; P < 0.001). Number needed to treat for benefit was 249 for death and 12 for remission.

Conclusion

Buprenorphine-naloxone was associated with significantly reduced mortality and increased remission rates for patients with opioid use disorder and should be used as a primary treatment. The recognition and implementation of treatment options like buprenorphine-naloxone is vital in alleviating the impact of OUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsHumansRetrospective StudiesFemaleMaleAdultMiddle AgedUnited StatesOpiate Substitution TreatmentAnalgesics, OpioidPropensity ScoreRemission InductionDrug OverdoseTreatment OutcomeBuprenorphine

Substanzen

Buprenorphine, Naloxone Drug CombinationNarcotic AntagonistsAnalgesics, OpioidBuprenorphine

Autor:innen und Institutionen

  • Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.
  • Department of Emergency Medicine, Michigan State University, East Lansing, Michigan.

Zitieren

APA

Paul, K. K., Frey, C. G., Troung, S., Paglicawan, L. V. Q., Cunningham, K. A., Preston Hill, T., Bothwell, L. G., Golovko, G., Pillay, Y., & Jehle, D. (2024). Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission. Western Journal of Emergency Medicine. https://doi.org/10.5811/westjem.18569

Vancouver

Paul KK, Frey CG, Troung S, Paglicawan LVQ, Cunningham KA, Preston Hill T, et al. Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission. Western Journal of Emergency Medicine. 2024. doi:10.5811/westjem.18569

BibTeX
@article{Paul2024,
  author = {Paul, Krishna K and Frey, Christian G and Troung, Stanley and Paglicawan, Laura Vita Q and Cunningham, Kathryn A and Preston Hill, T and Bothwell, Lauren G and Golovko, Georgiy and Pillay, Yeoshina and Jehle, Dietrich},
  title = {Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission},
  journal = {Western Journal of Emergency Medicine},
  year = {2024},
  doi = {10.5811/westjem.18569}
}
Kostenlos starten →